Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Enlivex Therapeutics stock

Learn how to easily invest in Enlivex Therapeutics stock.

Enlivex Therapeutics Ltd is a biotechnology business based in the US. Enlivex Therapeutics shares (ENLV) are listed on the NASDAQ and all prices are listed in US Dollars. Enlivex Therapeutics employs 50 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Enlivex Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ENLV – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Enlivex Therapeutics stock price (NASDAQ: ENLV)

Use our graph to track the performance of ENLV stocks over time.

Enlivex Therapeutics shares at a glance

Information last updated 2022-01-17.
Latest market close$5.80
52-week range$5.55 - $29.40
50-day moving average $6.92
200-day moving average $9.04
Wall St. target price$33.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.92

Buy Enlivex Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Stocks
$0
0%
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$0
$1 per month
$5
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Public
Stocks, ETFs, Cryptocurrency
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Enlivex Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Enlivex Therapeutics price performance over time

Historical closes compared with the close of $5.8 from 2022-01-19

1 week (2022-01-13) 0.35%
1 month (2021-12-20) -8.23%
3 months (2021-10-20) -34.39%
6 months (2021-07-20) -22.04%
1 year (2021-01-20) -51.67%
2 years (2020-01-17) -35.04%
3 years (2019-01-18) 460.44%
5 years (2017-01-20) 400.00%

Enlivex Therapeutics financials

Gross profit TTM $0
Return on assets TTM -14.42%
Return on equity TTM -26.76%
Profit margin 0%
Book value $4.81
Market capitalisation $107.6 million

TTM: trailing 12 months

Enlivex Therapeutics share dividends

We're not expecting Enlivex Therapeutics to pay a dividend over the next 12 months.

Have Enlivex Therapeutics's shares ever split?

Enlivex Therapeutics's shares were split on a 1:8 basis on 5 March 2019. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Enlivex Therapeutics shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Enlivex Therapeutics shares which in turn could have impacted Enlivex Therapeutics's share price.

Enlivex Therapeutics share price volatility

Over the last 12 months, Enlivex Therapeutics's shares have ranged in value from as little as $5.55 up to $29.4. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Enlivex Therapeutics's is 0.4608. This would suggest that Enlivex Therapeutics's shares are less volatile than average (for this exchange).

Enlivex Therapeutics overview

Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors.

Frequently asked questions

What percentage of Enlivex Therapeutics is owned by insiders or institutions?
Currently 12.398% of Enlivex Therapeutics shares are held by insiders and 12.377% by institutions.
How many people work for Enlivex Therapeutics?
Latest data suggests 50 work at Enlivex Therapeutics.
When does the fiscal year end for Enlivex Therapeutics?
Enlivex Therapeutics's fiscal year ends in December.
Where is Enlivex Therapeutics based?
Enlivex Therapeutics's address is: 14 Einstein Street, Ness Ziona, Israel, 7403618
What is Enlivex Therapeutics's ISIN number?
Enlivex Therapeutics's international securities identification number is: IL0011319527
What is Enlivex Therapeutics's CUSIP number?
Enlivex Therapeutics's Committee on Uniform Securities Identification Procedures number is: M20156101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site